RxDoctor Payments Data

Gregg Moody, MD

Ophthalmology · Athens, ALNPI 1982647731

Payments from drug & device makers

$1,556in general payments, 2019–2025

Across 93 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$83
  • Oyster Point Pharma, Inc.$82
  • Sun Pharmaceutical Industries Inc.$68
  • Aerie Pharmaceuticals, Inc.$58
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$52
  • plus $158 from 6 others

What the payments were for

  • Food & beverage$1,51197%
  • Gifts$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,556 in reported general payments places this provider in the 45th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$238,106
Medicare patients
1,025
Services billed
1,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost230$109,468
RestasisCyclosporine67$67,939
Cyclosporine62$53,081
XiidraLifitegrast16$21,597
Latanoprost887$16,096
Travoprost90$15,640
VyzultaLatanoprostene Bunod28$15,105
Restasis MultidoseCyclosporine13$13,655
SimbrinzaBrinzolamide/Brimonidine Tart43$9,096
CombiganBrimonidine Tartrate/Timolol31$8,862
MieboPerfluorohexyloctane/Pf12$8,736
Timolol Maleate235$6,103
Fluorometholone65$4,905
Prednisolone Acetate60$3,093
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat129$3,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose, Combigan, Alphagan P$1,056$202,190352 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$38$45,43756 claims
AlconSimbrinza$83$9,09643 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$52$1,60811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →